List of articles and reports
As referred to in the description of the NICE appraisals, there are several articles and reports that have been published in relation to this model. Several of these are listed below.
Web pages
The pathways pilot is mentioned as part of NICE’s webpage on taking a proportion approach to technology appraisals. [1] There are also then webpages available for each of the appraisals: the pathways pilot [2] and the appraisal of cabozatinib with nivolumab [3]
Reports
The above web pages link to relevant NICE reports, and these include….
- Final analysis plan for the model available as a PDF [4]
- Renal cell carcinoma pathway model report, which is “a summary of the external assessment group’s model and assumptions on renal cell carcinoma, discussed by NICE’s technology appraisal committee B”. Available as a PDF or within their website [5]
- NICE’s technology appraisal guidance on cabozatinib with nivolumab for untreated advanced renal cell carcinoma. Avaliable as a PDF or within their website [3]
And others from the appraisal history like:
Publications
There are several publications related to this analysis. When they are available under a permissive license, they have been embedded below.
An article describing the pathways pilot was published (along with a later correction):
- NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances - Lee et al. 2024 [6]
- Correction: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances - Lee et al. 2024 [7]
There is also a forthcoming monograph, though this is currently with a journal: Lee, Muthukumar, Lovell, et al. Treatments for renal cell carcinoma [ID6186]: A NICE Pilot Treatment Pathways Appraisal, HTA Monograph [Submitted].
Licensed under a CC-BY-NC-4.0 license.
Licensed under a CC-BY-NC-4.0 license.
A number of publications related to the UK Renal Oncology Collaborative (UK ROC) dataset used to inform baseline risk in the pathways model have also now been produced:
- Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the UK Renal Oncology Collaborative (UK ROC): Is it time to look favourably on first-line immunotherapy containing combinations in all IMDC groups? - McGrane et al. 2024 [8]
- Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC) - Frazer et al. 2024 [9]
- Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data - Lee et al. 2024 [10]
Licensed under a CC BY 4.0 license.
Licensed under a CC BY-NC-ND 4.0 license.
Licensed under a CC BY 4.0 license.
In addition, a publication investigating the issue of slippage in hazard ratios (tending towards the null over subsequent datacuts) for immune-oncology and TKI treatment combination treatment in first-line RCC has been produced:
- Slipping Away: Slippage in hazard ratios over datacuts and its impact on immuno-oncology combination economic evaluations - Lee et al. 2024 [11]